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Abstract
Background: Because insulin is the main regulator of glucose homeostasis,
quantitative models describing the dynamics of glucose-induced insulin secretion are
of obvious interest. Here, a computational model is introduced that focuses not on
organism-level concentrations, but on the quantitative modeling of local, cellular-
level glucose-insulin dynamics by incorporating the detailed spatial distribution of
the concentrations of interest within isolated avascular pancreatic islets.
Methods: All nutrient consumption and hormone release rates were assumed to
follow Hill-type sigmoid dependences on local concentrations. Insulin secretion rates
depend on both the glucose concentration and its time-gradient, resulting in
second-and first-phase responses, respectively. Since hypoxia may also be an
important limiting factor in avascular islets, oxygen and cell viability considerations
were also built in by incorporating and extending our previous islet cell oxygen
consumption model. A finite element method (FEM) framework is used to combine
reactive rates with mass transport by convection and diffusion as well as fluid-
mechanics.
Results: The model was calibrated using experimental results from dynamic glucose-
stimulated insulin release (GSIR) perifusion studies with isolated islets. Further
optimization is still needed, but calculated insulin responses to stepwise increments
in the incoming glucose concentration are in good agreement with existing
experimental insulin release data characterizing glucose and oxygen dependence.
The model makes possible the detailed description of the intraislet spatial
distributions of insulin, glucose, and oxygen levels. In agreement with recent
observations, modeling also suggests that smaller islets perform better when
transplanted and/or encapsulated.
Conclusions: An insulin secretion model was implemented by coupling local
consumption and release rates to calculations of the spatial distributions of all
species of interest. The resulting glucose-insulin control system fits in the general
framework of a sigmoid proportional-integral-derivative controller, a generalized PID
controller, more suitable for biological systems, which are always nonlinear due to
the maximum response being limited. Because of the general framework of the
implementation, simulations can be carried out for arbitrary geometries including
cultured, perifused, transplanted, and encapsulated islets.
Keywords: diabetes mellitus, FEM model, glucose-insulin dynamics, Hill equation,
islet perifusion, islets of Langerhans, oxygen consumption, PID controller
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In healthy humans, blood glucose levels have to be maintained in a relatively narrow
range: typically 4-5 mM and usually within 3.5-7.0 mM (60-125 mg/dL) in fasting sub-
jects [1,2]. This is mainly achieved via the finely-tuned glucose-insulin control system
whereby b-cells located in pancreatic islets act as glucose sensors and adjust their insu-
lin output as a function of the blood glucose level. Pancreatic islets are structurally
well-defined spheroidal cell aggregates of about one to two thousand hormone-secret-
ing endocrine cells (a, b, g, and PP-cells). Human islets have diameters ranging up to
about 500 μm with a size distribution that is well described by a Weibull distribution
function, and islets with diameters of 100-150 μma r et h em o s tr e p r e s e n t a t i v e[ 3 ] .
Because abnormalities in b-cell function are the main culprit behind elevated glucose
levels, quantitative models describing the dynamics of glucose-stimulated insulin
release (GSIR) are of obvious interest [1] for both type 1 (insulin-dependent or juve-
nile-onset) and type 2 (non-insulin dependent or adult-onset) diabetes mellitus. They
could help not only to better understand the process, but also to more accurately
assess b-cell function and insulin resistance. Abnormalities in b-cell function are criti-
cal in defining the risk and development of type 2 diabetes [4], a rapidly increasing
therapeutic burden in industrialized nations due to the increasing prevalence of obesity
[5,6]. A quantitative understanding of how healthy b-cells maintain normal glucose
levels is also of critical importance for the development of ‘artificial pancreas’ systems
[7] including automated closed-loop insulin delivery systems [8-10] as well as for the
development of ‘bioartificial pancreas’ systems such as those using immune-isolated,
encapsulated islets [11-13]. Accordingly, mathematical models have been developed to
describe the glucose-insulin regulatory system using organism-level concentrations,
and they are widely used, for example, to estimate glucose effectiveness and insulin
sensitivity from intravenous glucose tolerance tests (IVGTT). They include curve-fit-
ting models such as the “minimal model” [14] and many others [15-17] as well as para-
digm models such as HOMA [18,19]. There is also considerable interest in models
focusing on insulin release from encapsulated islets [20-26], an approach that is being
explored as a possibility to immunoisolate and protect transplanted islets.
The goal of the present work is to develop a finite element method (FEM)-based
model that (1) focuses not on organism-level concentrations, but on the quantitative
modeling of local, cellular-level glucose-insulin dynamics by incorporating the detailed
spatial distribution of the concentrations of interest and that (2) was calibrated by fit-
ting experimental results from dynamic GSIR perifusion studies with isolated islets.
Such perifusion studies allow the quantitative assessment of insulin release kinetics
under fully controllable experimental conditions of varying external concentrations of
glucose, oxygen, or other compounds of interest [27-30], and are now routinely used
to assess islet quality and function. Microfluidic chip technologies make now possible
even the quantitative monitoring of single islet insulin secretion with high time-resolu-
tion [31]. We focused on the modeling of such data because they are better suited for
a first-step modeling than those of insulin release studies of fully vascularized islets in
live organism, which are difficult to obtain accurately and are also influenced by many
other factors. Lack of vasculature in the isolated islets considered here might cause
some delay in the response compared with normal islets in their natural environment;
however, the diffusion time (L
2/D) [32] to (or from) the middle of a ‘standard’ islet (d
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the diffusion coefficients used here)-relatively small delays. Furthermore, because of
the spherical structure, most of the cell mass is located in the outer regions of the
islets (i.e., about 70% within the outer third of the radius) further diminishing the roles
of these delays.
By using a general approach that couples local (i.e., cellular level) hormone release
and nutrient consumption rates with mass transport by convection and diffusion, the
present approach allows implementation for arbitrary 2D or even 3D geometries
including those with flowing fluid phases. Hence, the detailed spatial distribution of
insulin release, hypoxia, and cell survival can be modeled within a unified framework
for cultured, transplanted, encapsulated, or GSIR-perifused pancreatic islets. While
there has been considerable work on modeling insulin secretion, no models that couple
both convective and diffusive transport with reactive rates for arbitrary geometries have
been published yet. Most published models incorporating mass transport focused on
encapsulated islets for a bioartificial pancreas [20-26]. Only very few [21,24] included
flow, and even those had to assume cylindrical symmetry. Furthermore, the present
model also incorporates a comprehensive approach to account not only for first-and
second-phase insulin response, but also for both the glucose-and the oxygen-depen-
dence of insulin release. Because the lack of oxygen (hypoxia) due to oxygen diffusion
limitations in avascular islets can be an important limiting [33] factor especially in cul-
tured, encapsulated, and freshly transplanted islets [27,28,34,35], it was important to
also incorporate this aspect of the glucose-insulin response in the model.
In response to a stepwise increase of glucose, normal, functioning islets release insu-
lin in a biphasic manner: a relatively quick first phase consisting of a transient spike of
5-10 min is followed by a sustained second phase that is slower and somewhat delayed
[36-39]. The effect of hypoxic conditions on the insulin release of perifused islets has
been studied by a number of groups [27,28,34,35], and they seem to indicate that insu-
lin release decreases nonlinearly with decreasing oxygen availability; however, only rela-
tively few detailed concentration-dependence studies are available. Parametrization of
the insulin release model here has been done to fit experimental insulin release data
mainly from two studies with the most detailed concentration dependence data avail-
able: by Henquin and co-workers for glucose dependence [40] and by Dionne, Colton
and co-workers for oxygen dependence [27].
In the present model, the insulin-secreting b-cells were assumed to act as sensors of
both the local glucose concentration and itsc h a n g e( F i g u r e1 ) .I nsulin is released
within the islets following Hill-type sigmoid response functions of the local (i.e., cellu-
lar level) glucose concentration, cgluc, as well as its time-gradient, ∂cgluc/∂t, resulting in
second-and first-phase insulin responses, respectively. Oxygen and glucose consump-
tion by the islet cells were also incorporated in the model using Michaelis-Menten-
type kinetics (Hill equation with nH = 1). Since lack of oxygen (hypoxia) can be impor-
tant in avascular islets [33], oxygen concentrations were allowed to limit the rate of
insulin secretion using again a Hill-type equation. Finally, all the local (cellular-level)
oxygen, glucose, and insulin concentrations were tied together with solute transfer
equations to calculate observable, external concentrations as a function of time and
incoming glucose and oxygen concentrations.
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Mass transport model (convective and diffusive)
For a fully comprehensive description, a total of four concentrations were used each
with their corresponding equation (application mode) for ‘local’ and released insulin,
glucose, and oxygen, respectively (cinsL, cins, cgluc,a n dcoxy). Accordingly, for each of
them, diffusion was assumed to be governed by the generic diffusion equation in its
nonconservative formulation (incompressible fluid) [32,41]:
∂c
∂t
+ ∇·(−D∇c)=R − u ·∇c (1)
where, c denotes the concentration [mol m
-3] and D the diffusion coefficient [m
2 s
-1]
of the species of interest, R the reaction rate [mol m
-3 s
-1], u the velocity field [m s
-1],
and ∇ the standard del (nabla) operator, ∇ = i
∂
∂x
+ j
∂
∂y
+ k
∂
∂z
[42]. The following diffu-
sion coefficients were used as consensus estimates of values available from the litera-
ture: oxygen, Doxy,w = 3.0 × 10
-9 m
2 s
-1 in aqueous media and Doxy,t =2 . 0×1 0
-9 m
2 s
-
1 in islet tissue ([33] and references therein); glucose, Dgluc,w =0 . 9×1 0
-9 m
2 s
-1 and
Dgluc,t =0 . 3×1 0
-9 m
2 s
-1; insulin, Dins,w =0 . 1 5×1 0
-9 m
2 s
-1 and Dins,t =0 . 0 5×1 0
-9
m
2 s
-1 [ 2 3 , 2 4 ] .P u b l i s h e dt i s s u ev a l u e sf o rg l u c o s ev a r yo v e raw i d er a n g e( 0 . 0 4 - 0 . 5×
10
-9 m
2 s
-1) [32,43-46]; a value toward the higher end of this range (0.3 × 10
-9 m
2 s
-1)
was used here. Very few tissue values for insulin are available (and the existence of
dimers and hexamers only complicates the situation) [32,47]; the value used here was
lowered compared to water in a manner similar to glucose. For the case of
Figure 1 Schematic concept of the present model of glucose-stimulated insulin release in b-cells.I t
is implemented within a general framework of sigmoid proportional-integral-derivative (SPID) controller,
and responds to glucose concentrations, but is also influenced by the local availability of oxygen. A total of
four concentrations are modeled for ‘local’ and released insulin (cinsL, cins), glucose (cgluc), and oxygen (coxy),
respectively.
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hydrogel matrices such as alginate): Doxy,c = 2.5 × 10
-9 m
2 s
-1, Dgluc,c = 0.6 × 10
-9 m
2 s
-
1, Dins,c = 0.1 × 10
-9 m
2 s
-1 [23,48].
Consumption and release rates
All consumption and release rates were assumed to follow Hill-type dependence on the
local concentrations (generalized Michaelis-Menten kinetics):
R = fH(c)=Rmax
cn
cn + Cn
Hf
(2)
The three parameters of this function are Rmax, the maximum reaction rate [mol m
-3
s
-1], CHf, the concentration corresponding to half-maximal response [mol m
-3], and n,
the Hill slope characterizing the shape of the response. This function introduced by A.
V. Hill [49,50] provides a convenient mathematical function for biological/pharmacolo-
gical applications [51]: it allows transition from zero to a limited maximum rate via a
smooth, continuously derivable function of adjustable width. Mathematically, the well-
known two-parameter Michaelis-Menten equation [52] represents a special case (n =
1) of the Hill equation, and eq. 2 also shows analogy with the logistic equation, one of
the most widely used sigmoid functional forms, being equivalent with a logarithmic
logistic function, y = f(x)=Rmax/(1 + be
-n lnx). Obviously, different parameter values
are used for the different release and consumption functions (i.e., insulin, glucose, oxy-
gen; e.g., CHf,gluc, CHf,oxy, etc.).
Oxygen consumption and cell viability
For oxygen consumption, the basic values used in our previous model [33,53] were
maintained (noxy =1 ,Rmax,oxy = -0.034 mol m
-3 s
-1, CHf,oxy =1μM-corresponding to a
partial oxygen pressure of pHf,oxy = 0.7 mmHg) since, by all indications, the assumption
of a regular Michaelis-Menten kinetics (i.e., noxy = 1) gives an adequate fit [54,55].
Accordingly, at very low oxygen concentrations, where cells only try to survive, oxygen
consumption scales with the available concentration coxy and, at sufficiently high con-
centration, it plateaus at a maximum (Rmax). As before [33], to account for the
increased metabolic demand of insulin release and production at higher glucose con-
centrations, a dependence of Roxy on the local glucose concentration was also intro-
duced via a modulating function o,g(cgluc):
Roxy = Rmax,oxy
coxy
coxy + CHf,oxy
· ϕo,g(cgluc) · δ(coxy > Ccr,oxy) (3)
A number of experiments have shown increased oxygen consumption rate in islets
when going from low to high glucose concentrations [56-58]. Here, in a slight update
of our previous model [33], we assumed that the oxygen consumption rate contains a
base-rate and an additional component that increases due to the increasing metabolic
demand in parallel with the insulin secretion rate (cf. eq. 6) as a function of the glucose
concentration:
ϕo,g(cgluc)=φsc
 
ϕbase + ϕmetab
c
nins2,gluc
gluc
c
nins2,gluc
gluc + C
nins2,gluc
Hf,ins2,gluc
 
(4)
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of the total rate possible (base = metab = 0.5). To maintain the previously used con-
sumption rate at low (3 mM) glucose, a scaling factor is used, Fsc = 1.8. The metabolic
component fully parallels that used for insulin secretion (nins2,gluc =2 . 5 ,CHf,ins2,gluc =7
mM; see eq. 6 later). With this selection, oxygen consumption increases about 70%
when going from low (3 mM) to high glucose (15 mM)-slightly less than used pre-
viously in our preliminary model [33], but in good agreement with the approximately
50%-100% fold increase seen in various experimental settings [35,36,56-60]. As before
[33], a step-down function, δ, was also added to account for necrosis and cut the oxy-
gen consumption of those tissues where the oxygen concentration coxy falls below a
critical value, Ccr,oxy =0 . 1μM (corresponding to pcr,oxy = 0.07 mmHg). To avoid com-
putational problems due to abrupt transitions, COMSOL’ss m o o t h e dH e a v i s i d ef u n c -
tion with a continuous first derivative and without overshoot flc1hs [61] was used as
step-down function, δ(coxy >Ccr,oxy) = flc1hs(coxy - 1.0x10
-4, 0.5x10
-4).
Glucose consumption
Glucose consumption, in a manner very similar to oxygen consumption, was assumed
to also follow simple Michaelis-Menten kinetics (ngluc =1 )w i t hRmax,gluc = -0.028 mol
m
-3 s
-1 and CHf,gluc =1 0μM [23,24,46]:
Rgluc = Rmax,gluc
cgluc
cgluc + CHf,gluc
(5)
These parameter values are draft first estimates only; however, changes in glucose
concentrations due to glucose consumption by islets have only minimal influence on
insulin release or cell survival because oxygen diffusion limitations in tissue or in
m e d i aa r ef a rm o r es e v e r et h a nf o rg l u c o s e[ 5 5 , 6 2 ] .E v e ni fo x y g e ni sc o n s u m e da t
approximately the same rate as glucose on a molar basis and has a 3-4-fold higher dif-
fusion coefficient (i.e., Dwsu s e dh e r eo f3 . 0×1 0
-9 vs. 0.9 × 10
-9 m
2 s
-1), this is more
than offset by the differences in the concentrations available under physiological condi-
tions. The solubility of oxygen in culture media or in tissue is much lower than that of
glucose; hence, the available oxygen concentrations are much more limited (e.g.,
around 0.05-0.2 mM vs. 3-15 mM assuming physiologically relevant conditions) [62].
Glucose consumption by islet cells alters the glucose levels reaching the glucose-sen-
sing b-cells only minimally.
Insulin release
Obviously, the most crucial part of the present model is the functional form describing
the glucose-(and oxygen) dependence of the insulin secretion rate, Rins.G l u c o s e( o r
oxygen) is not a substrate per se for insulin production; hence, there is no direct justifi-
cation for the use of Michaelis-Menten-type enzyme kinetics. Nevertheless, the corre-
sponding generalized form (Hill equation, eq. 2) provides a mathematically convenient
functionality that fits well the experimental results. A Hill function with n >1i s
needed because glucose-insulin response is clearly more abrupt than the rectangular
hyperbola of the Michaelis-Menten equation corresponding to n = 1 as clearly illu-
strated by the sigmoid-type curve of Figure 2 and by other similar data from various
sources [36,40,63,64]. In fact, such a function has been used as early as 1972 by
Grodsky (n =3 . 3 ,CHf,ins,gluc = 8.3 mM; isolated rat pancreas) and justified as resulting
from insulin release from individual packets with normally distributed sensitivity
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workers [65,66], such a sigmoid functional dependence has been mostly neglected
since then, and most models [21,23,24] used flatter (n = 1) response functions com-
bined with exponentially decreasing time-functions. To have a model that can be used
for arbitrary incoming glucose profiles, the use of explicit time dependency was
avoided here; however, use of an additional ‘local’ insulin compartment with first order
release kinetics (see later) achieves a similar effect. A sufficiently abrupt sigmoid
response function on cgluc ensures an upper limit (plateau) at high glucose concentra-
tions as well as essentially no response at low concentrations (Figure 2) eliminating the
need for a specified minimum threshold for effect.
Accordingly, the main function used here to describe the glucose-insulin dynamics of
the second-phase response is:
Rins,ph2 = Rmax,ins2
c
nins2,gluc
gluc
c
nins2,gluc
gluc + C
nins2,gluc
Hf,ins2,gluc
(6)
with nins2,gluc = 2.5, CHf,ins2,gluc = 7 mM, and Rmax,ins2 = 3.0 × 10
-5 mol m
-3 s
-1. These
values were obtained here by calculating the predicted insulin output in response to a
stepwise increase in incoming glucose and adjusting nins2,gluc and CHf,ins2,gluc to obtain
best fit with the human islet data of Henquin and co-workers (staircase experiment)
[40] (Figure 2). Topp and co-workers used a similar Hill function (n =2 ,CHf =7 . 8
mM) for insulin secretion based on (rat) data from Malaisse [67]. Compared to
Figure 2 Glucose-dependence of insulin secretion rate in perifused islets. Experimental data are for
perifused human islets (blue diamonds) [40] and isolated rat pancreas (blue circles) [63]. Fit of the human
data with general Hill-type equations (eq. 2) is shown without any restrictions (best fit, n = 2.7, CHf,gluc =
6.6 mM; blue line), with restricting the Hill slope to unity (n = 1, Michaelis-Menten-type function, CHf,gluc =
4.9 mM; dashed blue line), and with the present model used for the local concentration (eq. 6) (n = 2.5,
CHf,gluc = 7 mM; red line).
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cose concentration around 7 mM seems reasonable [40,68]. The activity of glucokinase,
which serves as glucose sensor in b-cells and is also generally considered as rate-limit-
ing for their glucose usage, shows a sigmoid-type dependence on cgluc (i.e., eq. 2 with
CHf,gluc =8 . 4m M ,ngluc = 1.7 [69] or CHf,gluc =7 . 0m M ,ngluc = 1.7 [70]) in general
agreement with eqs. 5 and 6 and their parameterization (Table 1). Rmax,ins2 corresponds
to a maximum (second phase) secretion rate of ~20 pg/IEQ/min for human islets
[37,40,71].
T oi n c o r p o r a t eas i m p l em o d e lo ft h ef i r s t - p h a s er e s p o n s e ,w ea l s oa d d e dac o m p o -
nent that depends on the glucose time-gradient (ct = ∂cgluc/∂t). This is non-zero only
when the glucose concentration is increasing, i.e., only when ct > 0. Again, a Hill-type
sigmoid response was assumed to ensure a plateau:
Rins,ph1 = Rmax,ins1
 
∂cgluc
∂t
 nins1,gluc
 
∂cgluc
∂t
 nins1,gluc
+ Ct
nins1,gluc
Hf,ins1,gluc
· σi1,g(cgluc) (7)
with nins1,gluc =2 ,CtHf,ins1,gluc =0 . 0 3m Ms
-1, and Rmax,ins1 = 21.0 × 10
-5 mol m
-3 s
-1.
These parameters are more difficult to directly calibrate from existing data on insulin
responses to stepwise glucose increases; hence, they have to be considered as explora-
tory settings. Constant glucose ramps have been explored with perifused rat islets in
an attempt to quantify these responses [72]; however, the gradients used there are too
small (1.5-4.5 μM/s) to allow a clear separation between first-and second-phase
responses for quantitation. The CtHf value used here (0.03 mM/s) was selected so as to
give an approximately linear response for a range that likely covers normal physiologic
conditions (e.g., 5 mM increase in 10-20 min: 0.005-0.01 mM/s) as well as dynamic
perifusion conditions (e.g., 2-6 mM increases in 1 min: 0.03-0.10 mM/s). A completely
linear (i.e., proportional) glucose gradient dependent term has been used in a few pre-
vious models mainly following Jaffrin [20,26,72-74] (one of them [73] also allowing
modulation of the proportionality constant by glucose concentration). Here, one
Table 1 Summary of Hill function (eq. 2) parameters used in the present model (Figure
1, eq. 3-9)
Model Var. CHf nR max Comments
Roxy, oxygen
consumption,
base
coxy 1 μM 1 -0.034 mol/m
3/s Cut to 0 below critical value, coxy <Ccr,oxy.
Roxy, oxygen
consumption, o,g
metabolic part
cgluc 7 mM 2.5 N/A Due to increasing metabolic demand;
parallels second-phase insulin secretion
rate.
Rgluc, glucose
consumption
cgluc 10 μM 1 -0.028 mol/m
3/s Contrary to oxygen, has no significant
influence on model results.
Rins,ph2, insulin
secretion rate,
second-phase
cgluc 7 mM 2.5 3 × 10
-5 mol/m
3/s Total secretion rate is modulated by local
oxygen availability (last row).
Rins,ph1, insulin
secretion rate,
first-phase
∂cgluc/∂t 0.03 mM/s 2 21 × 10
-5 mol/m
3/s Modulated via eq. 8 to have maximum
sensibility around cgluc = 5 mM and be
limited at very large or low cgluc.
Insulin secretion
rate, o,g oxygen
dependence
coxy 3 μM 3 N/A To abruptly limit insulin secretion if coxy
becomes critically low.
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ent-dependent response for islets that are already operating at an elevated second-
phase secretion rate and to maximize it around cgluc values where islets are likely to be
most sensitive (Cm = 5 mM) using a derivative of a sigmoid function:
σi1,g(cgluc)=
4c4
glucC4
m
 
c4
gluc + C4
m
 2 (8)
With all these, total insulin release is obtained as the sum of first-and second-phase
releases and an additional modulating function to account for the limiting effect of
oxygen availability, which can become important in the core region of larger avascular
islets especially under hypoxic conditions:
Rins =( Rins,ph1 + Rins,ph2) · ϕi,o(coxy) (9)
We assumed an abrupt Hill-type (eq. 2) modulating function as i,o(coxy)w i t hnins,oxy =
3 and CHf,ins,oxy =3μM( pHf,ins,oxy = 2 mmHg) so that insulin secretion starts becoming
limited for local oxygen concentrations that are below ~6 μM (corresponding to a partial
pressure of pO2 ≈ 4 mmHg) (Additional file 1, Figure S1). This is a somewhat similar,
but mathematically more convenient function than the bilinear one introduced by
Avgoustiniatos [75] and used by Colton and co-workers [76] to account for insulin
secretion limitations at low oxygen (pO2 < 5.1 mmHg assumed by them) as it is a
smooth sigmoid function with a continuous derivative (Additional file 1, Figure S1).
For a correct time-scale of insulin release, an extra compartment had to be added;
otherwise insulin responses decreased too quickly compared to experimental observa-
tions (~1 min vs. ~5-10 min). Hence, insulin is assumed to be first secreted in a ‘local’
compartment (Figure 1) in response to the current local glucose concentration (Rins,
eq. 9) and then released from here following a first order kinetics [dcinsL/dt = Rins -
kinsL(cinsL - cins); kinsL =0 . 0 0 3s
-1, corresponding to a half-life t1/2 of approximately 4
min]. ‘Local’ insulin was modeled as an additional concentration with the regular con-
vection model (eq. 1), but having a very low diffusivity (DinsL,t =1 . 0×1 0
-16 m
2 s
-1).
Throughout the entire model building process, special care was taken to keep the
number of parameters as low as possible to avoid over-parameterization [77]; however,
inclusion of this compartment was necessary. The model has been parameterized by
fitting experimental insulin release data from two detailed concentration-dependence
perifusion studies: one concentrating on the effect of glucose using isolated human
islets [40] and one concentrating on the effect of hypoxia using isolated rat islets [27].
Fluid dynamics model
To incorporate media flow in the perifusion tube, these convection and diffusion mod-
els need to be coupled to a fluid dynamics model. Accordingly, the incompressible
Navier-Stokes model for Newtonian flow (constant viscosity) was used for fluid
dynamics to calculate the velocity field u that results from convection [32,41]:
ρ
∂u
∂t
− η∇2u + ρ(u ·∇)u + ∇p = F
∇·u =0
(10)
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-3], h viscosity [kg m
-1 s
-1 = Pa s], p pressure [Pa, N m
-
2,k gm
-1 s
-2], and F volume force [N m
-3,k gm
-2 s
-2]. The first equation is the
momentum balance; the second one is simply the equation of continuity for incom-
pressible fluids. The flowing media was assumed to be an essentially aqueous media at
body temperature; i.e., the following values were used: T0 =3 1 0 . 1 5K ,r = 993 kg m
-3,
h=0 . 7×1 0
-3 Pa s, cp = 4200 J kg
-1K
-1, kc =0 . 6 3 4Js
-1m
-1K
-1, a =2 . 1×1 0
-4 K
-1.A s
previously [33], incoming media was assumed to be in equilibrium with atmospheric
oxygen and, thus, have an oxygen concentration of coxy,in = 0.200 mol m
-3 (mM) corre-
sponding to pO2 ≈ 140 mmHg. A number of GSIR perifusion studies including [40]
used solutions gassed with enriched oxygen (e.g., 95% O2 +5 %C O 2; pO2 ≈ 720
mmHg); however, with the islet sizes used here, atmospheric oxygen already provides
sufficient oxygenation so that the extra oxygen has no effect on model-calculated insu-
lin secretion (see Results section). Inflow velocity was set to vin =1 0
-4 ms
-1 (corre-
sponding to a flow rate of 0.1 mL/min in a~ 4m mt u b e ) ,a n da l o n gt h ei n l e t ,a
parabolic inflow velocity profile was used: 4vins(1-s), s being the boundary segment
length.
Model implementation
The models were implemented in COMSOL Multiphysics 3.5 (formerly FEMLAB;
C O M S O LI n c . ,B u r l i n g t o n ,M A )a n ds o l v e da s time-dependent (transient) problems
allowing intermediate time-steps for the solver. Computations were done with the Par-
diso direct solver as linear system solver with an imposed maximum step of 0.5 s,
which was needed to not miss changes in the incoming glucose concentrations that
could be otherwise overstepped by the solver. With these setting, all computation
times were reasonable being about real time; i.e., about 1 h for each perifusion simula-
tions of 1 h interval.
As a representative case, a 2D cross-section of a cylindrical tube with two spherical
islets of 100 and 150 μm diameter was used allowing for the possibility of either free
or encapsulated islets (capsule thickness l =1 5 0μm; fluid flowing from left to right)
(Figure 3). Stepwise increments in the incoming glucose concentration were implemen-
ted using again the smoothed Heaviside step function at predefined time points ti, cgluc
= clow + Σcstep,i flc1hs(t - ti, τ). For FEM, COMSOL’s predefined ‘Extra fine’ mesh size
was used (5,000-10,000 mesh elements; Figure 3). In the convection and diffusion
models, the following boundary conditions were used: insulation/symmetry, n (-D∇c
+cu) = 0, for walls, continuity for islets. For the outflow, convective flux was used for
insulin, glucose, and oxygen, n (-D∇c) = 0. For the inflow, inward flux was used for all
components with zero for insulin (N0 =0 ) ,cgluc vin for glucose, and coxy,in vin for oxy-
gen. In the incompressible Navier-Stokes model, no slip (u = 0) was used along all sur-
faces corresponding to liquid-solid interfaces. For the outlet, pressure, no viscous stress
with p0 = 0 was imposed.
For visualization of the results, surface plots were used for cins, coxy, and Rins.F o r3 D
plots, cins was also used as height data. A contour plot (vector with isolevels) was used
for cgluc to highlight the changes in glucose. To characterize fluid flow, arrows and
streamlines for the velocity field were also used. Animations were generated with the
same settings used for the corresponding graphs. Total insulin secretion as a function
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boundary.
Results and Discussion
First-and second-phase insulin responses
Following implementation of the model, the values of the adjustable parameters of eqs.
4-9 were selected (Table 1) so as to fit insulin secretion data from islet perifusion
experiments with detailed dose responses for glucose-[40,78] and oxygen-dependence
[27]. For this purpose, model-predicted insulin responses to stepwise increments in the
incoming glucose content were calculated as boundary integrals on the exiting surface
of the out-flowing fluid, and these were then fitted to the experimental insulin
responses measured as a function of time. First, the parameters of the second-phase
response (eq. 6) were fitted to the results of the staircase experiment [40], then those
of the first-phase response (eq. 7 and 8). Fine-tuning of the values has been done in a
few iterative rounds to also fit the oxygen dependence [27]. As Figure 4 shows, accep-
table quantitative agreement can be obtained for both phase 1 and phase 2 responses
of the insulin secretion of human islets as measured recently in detailed experiments
[40]. The amplitude of the insulin response, which depends on the mass of functional
islets present, was adjusted for best fit, but it is within the expected range if calculated
for the corresponding number of islet equivalents (IEQ). During the modeling [79], it
became apparent that in order to have a correct time-scale and not a very short-term
first-phase release, some delay mechanism has to be introduced. After exploring several
possibilities, the delay was modeled by incorporation of a ‘localized’ insulin compart-
ment (e.g., intracellular) from which insulin is then released to the surroundings via
Figure 3 Geometry and a representative mesh used for the present FEM model. Two representative
spherical islets, which can be either free or encapsulated, are included in a tube with fluid flowing from
left to right.
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Page 11 of 25first order kinetics (kinsL) (Figure 1). A main reason for this choice was that concep-
t u a l l y ,t oag o o de x t e n t ,t h i si nsulin secreted and stored ‘locally’ can be considered as
the insulin in the readily releasable pool (RRP) of granules in current dynamic cellu-
lar models of biphasic insulin secretion [37,65]. It is being filled in response to glu-
cose stimulation (Rins, eq. 9) and then gradually emptied (kinsL). Our goal at this
point, is not to model the detailed cellular and subcellular mechanisms responsible
for the biphasic secretion and the staircase response [37,65,66], but to identify func-
tional forms for local responses (Rins)t h a tw h e ni n t e g r a t e dw i t ht h ed e s c r i p t i o n so f
spatial distribution of the relevant concentrations can give an adequate quantitative
description (cgluc, coxy ® Rins ® cins). Most perifusion experiments intended to assess
islet quality are performed as single step low-high-low glucose perifusion experi-
ments; a fit for one such data is shown in Figure 5. Again, except for an underesti-
mate of the first-phase peak, acceptable agreement is obtained. First-phase insulin
secretion has been shown to be greater following a larger step-up in glucose to the
same final value (e.g., both in human [40] and in mouse [80] islets). The present
model should account for this as its first-phase insulin secretion rate is determined
by the glucose gradient, which increases directly with the size of the step-up; how-
ever, some fine-tuning of the parameters is still needed. The predicted first-phase
decay (resulting from kinsL) may be a bit too slow (t1/2 ≈ 4m i n ) ;h o w e v e r ,t h ep r e d i c -
tion of the second-phase decay is more adequate, and to keep the model as simple as
possible, we chose to use only one single ‘local’ insulin ‘compartment’, hence, a single
first-order release rate kinsL.
Figure 4 Glucose-induced insulin secretion in perifused human islets in response to stepwise
glucose increments. Glucose concentration in the perifusing solution increases from 1 mM (G1) to 30
mM (G30) as indicated. Values calculated with the present model (red line, — ) are shown superimposed
on the same time-scale over data determined experimentally (blue disks, ●; redrawn from [40]).
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Because oxygen diffusion is a limiting factor in avascular islets, hypoxia can limit insu-
lin secretion. The oxygen dependence of local insulin release has been parameterized
so as to fit the only detailed data available, which, however, are for rat islets [27]. Insu-
lin secretion profiles calculated here for different incoming oxygen concentrations in
response to a single glucose step are shown in Figure 5 for a few representative cases.
A sF i g u r e6s h o w s ,t h e yg i v eag o o dq u a n t i t a t i v ef i to ft h ee x p e r i m e n t a ld a t ao fr e f e r -
ence [27]. The problem, however, is complicated by the fact that due to the larger dif-
fusion distance, hypoxia is much more severe in the core regions of larger islets [33];
hence, hypoxia will have different effects on the insulin response of differently sized
islets. This can be seen in Figure 7 and Figure 8, which show the calculated spatial dis-
tributions of insulin, oxygen, and glucose concentrations under normoxic and slightly
hypoxic conditions as surface plots. Figure 9 provides further illustration by comparing
oxygen concentrations and insulin secretion rates along a vertical cross section of the
two islets.
Accordingly, the overall experimental response to hypoxic conditions will depend on
the size-distribution of the islet sample. Human islets seem to follow a Weibull distri-
bution with the expected value of islet diameter being around 95 μm and the expected
Figure 5 Oxygen dependence of the calculated GSIR in perifused human islets. Calculated insulin
outflow in response to a stepwise glucose increment from 1 mM (G1) to 15 mM (G15) and back for
different incoming oxygen concentrations as indicated by the pO2 values shown at right. For the normoxic
values (red line, —), corresponding values determined experimentally (blue circles, ○; redrawn from [40])
are also shown for comparison.
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6 μm (corresponding to an islet with d =1 3 3μm)
[3]. In other words, most (human) islets are expected to have a diameter around 100
μm, but most of the islet mass (volume) is coming from islets with a diameter around
150 μm, which has been traditionally used as the standard islet (islet equivalent, IEQ)
[81,82]. Consequently, we chose two islets with d = 100 and 150 μma sr e p r e s e n t a t i v e
for our simplified modeling.
It is important to note that even though local insulin release is becoming limited
only for oxygen concentrations below 4 mmHg (≈6 μM; eq. 9), the total insulin secre-
tion of the islets starts decreasing rapidly if surrounding oxygen levels drop below ~50
mmHg and is already half-maximal around 25 mmHg (Figure 6). The reason, of
course, is that oxygen concentrations in the core of larger islets are considerable less
than in the surrounding media due to diffusion limitations (see Figure 8 and 9). It is
also worth noting that overall insulin response remains essentially unchanged until
oxygen pressures decrease down to ~50 mmHg (Figure 6), values that are present in
well vascularized tissues, and then decreases rapidly. This agrees well even with results
of in vivo experiments in dogs suggesting that moderate hypoxia (pO2 ≈ 40 mmHg)
does not affect insulin response, whereas more severe hypoxia (pO2 ≈ 25 mmHg) mark-
edly inhibits it [83]. A number of GSIR perifusion studies including [40] used solutions
gassed with enriched oxygen (e.g., 95% O2 +5 %C O 2; pO2 ≈ 720 mmHg). Compared to
atmospheric oxygen (pO2 ≈ 140 mmHg), this does not produces any changes in the
insulin profile calculated with the present model (e.g., Figure 4) since with the islet
sizes used here atmospheric oxygen already provides sufficient oxygenation so that
insulin secretion is not limited (Figure 8A, Figure 9A). On the other hand, transplanted
Figure 6 Influence of oxygen concentration on the insulin secretion rate of perifused islets.D a t a
represent the fraction of normoxic (second-phase) rate at various oxygen levels in the perifusing media;
experimental data (blue triangles) are from [27] and values calculated here are shown as red disks for free
islets and orange circles for encapsulated islets. The size-distribution of the islet sample influences these
results as larger islets are more severely affected by hypoxia.
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seeding density and the vascularization of the surrounding tissue, which can further
limit their insulin secreting ability. Availability of oxygen is the main limiting factor
because, under physiological conditions, oxygen concentrations are considerably lower
than glucose concentrations (e.g., around 0.05-0.2 mM vs. 3-15 mM) [62], and this is
well illustrated by the present calculation in Figure 8 that compares oxygen and
Figure 7 Comparison of the calculated insulin distribution and secretion rate under various
conditions. Model calculated concentrations during an increase of incoming glucose to 10 mM
(corresponding to t = 120.5 min in Figure 4) in two perifused islets (d = 100 and 150 μm; flow from left to
right) under normoxic conditions (A), slightly hypoxic conditions (45 mmHg) (B), and slightly hypoxic
conditions and encapsulation (C). Data shown as surface plot are insulin concentration (1; shown color-
coded from blue for low to red for high-note different scales) and total insulin secretion rate (eq. 9) (2;
color-coded from green for 0 to red for high and shown on same scale). Gray streamlines and arrows
illustrate the velocity field of the flowing perifusion fluid, and colored contour lines show isolevels for the
perifusing glucose.
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of larger islets are only a few percent lower than at the periphery, oxygen concentra-
tions in the center are considerably lower than at the periphery. R. T. Kennedy and
co-workers measured somewhat larger glucose concentration decreases in the center of
cultured islets (10-20%) [45], but even those are much less severe than the correspond-
ing oxygen decreases.
With the calibrated model, detailed simulations for arbitrary inflow conditions and
for arbitrary islet arrangements can be performed, and corresponding detailed graphics
Figure 8 Comparison of the calculated oxygen and glucose concentrations under various
conditions. Model calculated concentrations in two perifused islets under the same conditions as in
Figure 7: normoxic (A), slightly hypoxic (45 mmHg) (B), and slightly hypoxic and encapsulation (C). Data
shown as surface plot are oxygen concentration (3; shown color-coded from red for low to blue for high
with white indicating levels below the critical value Ccr,oxy) and glucose concentration (4; shown color-
coded from blue for low to red for high). Oxygen concentrations are shown during an increase of
incoming glucose to 10 mM (same as in Figure 7); glucose concentrations are shown at a slightly later
time point at a constant incoming glucose of 10 mM to avoid the masking effect of the incoming glucose
gradient. Note differences in scale between oxygen and glucose, glucose concentrations decreasing by a
much smaller percentage than oxygen.
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Page 16 of 25Figure 9 Comparison of oxygen levels and insulin secretion rates along a vertical cross section.
Calculated values along the vertical mid-section of Figure 3 (or Figure 7) through the two perifused islets
under normoxic conditions (atmospheric oxygen, 140 mmHg) (A), hypoxic conditions (resembling tissue
oxygen concentrations, 45 mmHg) (B), and hypoxic conditions and encapsulation (C). The two sets of
color-coded curves in each figure indicate calculated oxygen concentrations and insulin secretion rates,
respectively at various time-points corresponding to glucose concentrations of 3, 5, 7, and 10 mM. At
oxygen concentrations that transplanted islets are likely to encounter in their surrounding tissue (~40
mmHg), the insulin secretion of the core region of larger islets is severely compromised.
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glucose concentrations along the perifusion chamber with two islets during a glucose
gradient are shown in Figure 7 together with the insulin secretion rates. A set of simi-
lar results is shown in Figure 9 along a vertical cross-section through the middle of
these figures. To illustrate the easy generalizability of the present approach, Additional
file 1, Figure S2 shows the results of calculations obtained for a case where a support-
ing filter was included in the tube. While this perturbs the flow, it has essentially no
effect on the overall insulin output justifying the simplifying assumptions made for the
present geometry (Figure 3). Increases in the perifusion rate (e.g., up to ten-fold) also
have no significant effect on calculated insulin output.
Figure 10 shows 3D graphs with insulin as height data and color-coded for the oxy-
gen concentrations to further highlight the results of decreasing oxygen concentration
i nt h ec o r er e g i o no fl a r g e ri s l e t s .Ac o r r e sponding set of animations are included as
Supporting Information to illustrate the time-course of the first-and second-phase
responses following a glucose step (Additional file 2, Video S1; Additional file 3, Video
S2). At normoxic conditions (pO2 = 140 mmHg in the incoming media), the core
region of even large islets is still sufficiently oxygenized due to the flowing media;
hence, their insulin secretion is not limited. However, this is no longer true for hypoxic
Figure 10 Calculated insulin concentrations shown as height data. Surfaces are color-coded for
oxygen concentration (blue high, red low) for the same configuration and time-point shown in Figure 7
for free islets in normoxic (pO2 = 140 mmHg) (A) and hypoxic conditions (pO2 = 25 mmHg) (B) as well as
for encapsulated islets in normoxic conditions (C). The insulin secreting ability of the large islet is more
severely affected by hypoxia as clearly indicated by the changes in relative height between A and B (note
different scales).
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results for pO2 of 45 and 25 mmHg, respectively in the incoming media. Contrary to
the previous case, the two islets are predicted to secret about similar insulin amounts
despite their different sizes due to the more severe oxygen limitations in the core
region of the larger islet, which restricts insulin secretion to an outside shell only in
large islets. These results are in good agreement with observations suggesting that
smaller islets tend to perform better in islet transplantation (with or without encapsu-
lation) [85-88].
Encapsulated islets
In patients with type 1 diabetes mellitus, the transplantation of pancreatic islet cells
can normalize metabolic control in a way that has been virtually impossible to
achieve with exogenous insulin, and is being explored, in a selected cohort of patients
with brittle diabetes, as an experimental therapy [89,90]. To avoid the need for life-
long immunosuppression, islet encapsulation using semi-permeable membranes and
various techniques has long been explored as a possible approach to develop a bioar-
tificial pancreas-an organ capable of releasing insulin in a biomimetic manner in
response to plasma glucose changes [11-13].M a n yf a i l e da t t e m p t s[ 9 1 ]m a d ei tc l e a r
that minimizing the extra volume of encapsulating material (as well as cellular over-
growth) and the corresponding diffusional limitations are crucial for graft success.
Hence, there is a considerable interest in modeling the insulin responses of such
devices [20-26].
Encapsulated islets remain avascular; hence, the present software can be easily
extended to model their behavior under perifusion or tissue transplant conditions. For
example, as Figure 11 shows, simulations with the present model for microencapsu-
lated islets (assuming hydrogel-like encapsulating material of a relatively modest width,
l =1 5 0μm) predicts that perifusion results in somewhat delayed and dampened insu-
lin response, but insulin response kinetics is maintained to a good degree. This is in
good agreement with some experimental results obtained, for example, with alginate
microencapsulated islets (using oxygen-enriched perifusion media to minimize the
effects of oxygen limitation) [92,93]. However, at lower perifusing oxygen concentra-
tions, such as those mimicking tissue oxygen concentrations that transplanted islets
are likely to encounter even in well-vascularized tissue (pO2 = 35-45 mmHg; coxy =
0.05-0.065 mM), the loss in insulin secreting ability is much more significant as the
encapsulated islets here suffer much more heavily from hypoxia (Figure 7, Figure 9,
and Figure 10). Whereas, under these conditions, free islets can still secrete insulin at
around 70-75% of their normal rate (and, for transplanted islets, will improve with
time as their vasculature is restored), encapsulated islets can only operate at around
5 0 %o ft h ef u l lr a t ea n dt h e i rr esponse is especially hampered at larger glucose levels
(Figure 6, Figure 11). As nicely illustrated by Figure 7 and Figure 9, only a relatively
small percentage of the encapsulated islets cells is able to secrete insulin at full capa-
city; oxygen diffusion limitations severely restrict the hormone secreting ability of the
core regions even at this relatively thin microcapsule size-further emphasizing the need
for conformal/nano-coating or other alternative approaches [13,94,95]. These results
reconfirm the finding of some previous modeling work with cultured or encapsulated
islets [75,76], which focused on the limiting effect of hypoxia but without incorporating
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(or islet cell aggregates) could reduce the impact of oxygen diffusion limitation.
Modeling considerations
Obviously, this is still a much simplified, exploratory model; the actual mechanism of
glucose-induced insulin secretion in b-cells is complex and involves various molecular-
level events [1,2,36,37,39,70,96,97]. The present model gives an adequate quantitative
description of the main distinctive features of insulin release, but, at this stage, does
not account for interspecies differences and does not incorporate a number of effects
known to affect glucose-induced insulin release including, e.g., amplifiers such as glu-
cagon-like peptide-1 (GLP-1) as well as time-dependent effects (i.e., both time-depen-
dent inhibition and potentiation; e.g., the “glucose priming” effect) [98].
One of the most complex technical control systems that is widely used in industrial
control systems and has been suggested as a possibility for the glucose-insulin control
system is the proportional-integral-derivative controller (PID controller) [1,8-10]. PID
controllers are also particularly promising for closed-loop insulin delivery systems with
continuous glucose sensors [8-10,99]. This control loop feedback mechanism uses a
combination of proportional, integral, and differential (PID) terms so that the control
signal has elements that are functions of the error signal itself (ε = ξ - ξo, the difference
Figure 11 Calculated GSIR in perifused free vs. encapsulated islets. Insulin outflow calculated in
response to stepwise glucose increments from 1 mM (G1) to 30 mM (G30) under normoxic (continuous
line, pO2 = 140 mmHg) and slightly hypoxic (dashed line; pO2 = 45 mmHg) conditions for free (red) vs.
encapsulated islets (orange). The response of normoxic free islets is the same as given in Figure 4.
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ential (dε/dt). In other words, the controller output signal ψ can be written as a func-
tion of time as:
ψPID(t)=αpε(t)+αi
t  
0
ε(τ)dτ + αd
dε(t)
dt
(11)
PID control works great in linear systems; however, biological systems are never fully
linear: proportional responses are only possible over some limited range as biological
responses (e.g., hormone secretion rates, enzymatic degradation rates, nerve firing
rates, etc.) are always limited between zero and some maximum value. Biologic systems
are always nonlinear, never stationary, but robust, which often comes from coupling of
different, overlapping systems [1]. Accordingly, responses in biologic systems are much
better described by sigmoid functions; hence, the present suggestion for sigmoid pro-
portional-integral-derivative controllers (SPID controllers) for biologic responses. Use
of the Hill function fH (eq. 2) allows sigmoid responses with limited maximum rates
(Rmax) and flexible shapes (n):
ψSPID(t)=αpfH[ε(t)] + αifH
⎡
⎣
t  
t−θ
ε(τ)dτ
⎤
⎦ + αdfH
 
dε(t)
dt
 
(12)
H e r e ,w eu s e dt h es i g m o i dd i r e c t( p r o p o r t i o n a l )t e r mt om o d e lt h eo x y g e na n dg l u -
cose consumptions as well as the second phase insulin release, and the sigmoid differ-
ential term to model the first-phase insulin release (with cgluc itself as the “error” signal
ε; Figure 1). As always, the role of the differential term is to speed up the system; i.e.,
to give a large correction signal as soon as possible when the monitored value changes
suddenly-exactly the role played by the first-phase insulin secretion. In the present
model, we could not yet implement an integral term despite a clear need for such a
term over a specified time interval to account, for example, for some inertia and/or
delay in insulin secretion (integral control is part of several models, i.e.,
[8-10,73,99,100]). However, addition of the extra compartment for delayed insulin
release actually incorporates some elements usually accounted for by such an integral
term.
Conclusion
In conclusion, a comprehensive insulin secretion model for avascular pancreatic islets
has been implemented using Hill-type sigmoid response functions to describe both glu-
cose and oxygen dependence. Detailed spatial distributions of all concentrations of
interest are incorporated and coupled via local consumption and release functions. Fol-
lowing parameterization, good fit could be obtained with experimental perifusion data
of human islets. Further optimization of the model is required; however, the present
approach makes it relatively straightforward to couple arbitrarily complex hormone
secretion and nutrient consumption kinetics with diffusive and even convective trans-
port and run simulations with realistic geometries without symmetry or other restric-
tions-problems that seriously limited previous glucose-insulin modeling attempts.
Because of the general framework of the implementation, the model not only helps in
the elucidation of the quantitative aspects of the insulin secretion dynamics, but also
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transplanted, or encapsulated islets including the simulation of GSIR perifusion experi-
ments or the study of the performance of bioartificial pancreas type devices.
Additional material
Additional file 1: Supporting Information, Figures S1 and S2. Two supporting figures with Figure S1 showing
the local oxygen-dependent modulating function and Figure S2 showing model calculations with a supporting
filter included in the perifusion tube.
Additional file 2: Supporting Information, Video S1. Movie file showing the time-course of the insulin response
of two islets to a glucose step (3 mM ® 11 mM ® 3 mM) under normoxic conditions (pO2 140 mmHg) in a 3D
representation with insulin concentration as height data and a surface color-coded for oxygen concentration
(similar to Figure 10).
Additional file 3: Supporting Information, Video S2. Movie file showing the time-course of the insulin response
of two islets to a glucose step (3 mM ® 11 mM ® 3 mM) under hypoxic conditions (pO2 25 mmHg) in a 3D
representation with insulin concentration as height data and a surface color-coded for oxygen concentration
(similar to Figure 10).
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